Samuel D. Ang, Roel S. Tolentino, Deo Reyes,
Conrado C. Cajucom Related Institution
Publication Sub Type
Journal Article, Original
Philippine Journal of Surgical Specialties
OBJECTIVE: This study was designed to determine the effect of age, size of tumor, number of positive axillary nodes and the different adjuvant treatments on the disease-free survival and overall survival of a group of patients with locally advanced invasive ductal carcinoma not treated with neoadjuvant therapy.
METHODS: All breast cancer patients seen by the senior author at St. Luke's Medical Center, Chinese General Hospital and Cardinal Santos Medical Center from January 1980 to October 2000 were reviewed. Of the 415 breast cancer patients seen, 78 locally advanced breast cancer patients who did not undergo neoadjuvant treatment but underwent modified radical mastectomy and subsequent adjuvant therapy were included in this study.
RESULTS: The mean age of the patients was 49 years and the mean tumor size was 5.4 centimeters. The median follow-up was 35 months (range=3-180 months). There were 47 recurrences (11 percent) and 24 (5 percent) deaths and the average time to recurrence was 23 months. There were no significant linear correlations between age, tumor size and number of positive lymph nodes on the disease-free survival and overall survival (p0.05). Likewise, there was no significant difference on the disease-free survival between the patients treated by anyone of the four mentioned adjuvant treatments (p0.05). However, those who received chemotherapy and hormonal therapy had a significantly longer overall survival compared to those who received either one of the three other adjuvant treatments (p0.05). Postoperative radiotherapy did not appear to offer a significantly longer disease-free and overall survival. CONCLUSION: In locally advanced breast cancer patients who did not receive neoadjuvant treatment, increasing age, increasing size of the breast tumor and increasing number of positive axillary nodes did not correlate significantly to shorter disease free survival and overall survival. Postoperative chemotherapy and hormonal therapy combination without radiotherapy showed a trend of longer overall survival in selected patients. References
1. Rubens, RD . "Management of advanced breast cancer"
Int J Clin Pract 55, 173-178, 2001
2. Gioffre Florio, MA , Fama, F , Giacobbe, G , Pollicino, A , Scarfo, P . "Surgical treatment of breast cancer after neoadjuvant therapy"
55, 173-178, 2003. Retrieved from:
3. Hortobagyi, GN , Singletary, SE , Strom, EA , Lippman, ME , Morrow, M , Osborne, CK , Harris, JR . Treatment of locally advanced breast cancer. Diseases of breast Philadelphia: Lippincott, Williams and Wilkins, 2000. 645-660. (2nd ed)
4. Esteva, FJ , Hortobagyi, GN . "Locally advanced breast cancer"
Hematol Oncol Clin North Am 13, 457-472, 1999
5. Bartelink, H , Rubens, RD , van der Schueren, E , Sylvester, R . "Hormonal theraphy prolongs survival in irradiated locally advanced breast cancer, a european organization for research and treatment for cancer randomized phase III trial"
J Clin Oncol
15, 207-215, 1997. Retrieved from:
7. Sikov, WM . "Locally advanced breast cancer"
Curr Treat Options Oncol 1, 228-238, 2000
8. Gianni, L , Valagussa, P , Zambetti, M , Moliterni, A , Capri, G , Bonadonna, G . "Adjuvant and neojuvant treatment of breast cancer"
28, 13-29, 2001. Retrieved from:
9. Hutcheon, AW , Heys, SD , Sarkar, TK , Aberdeen Breast Grou, . "Neoadjuvant docetaxel in locally advanced breast cancer"
Breast Cancer Res Treat
79(Suppl 1): S 19-24, 2003. Retrieved from:
10. McIntosh, SA , Ogston, KN , Payne, S , et al., . "Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy"
Am J Surg
(185): 525-531, 2003. Retrieved from:
11. Coskun, U , Gunel, N , Onuk, E , et al., . "Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer"
50, 210-216, 2003. Retrieved from:
12. Dank, M , Zergenyi, E , Domotori, ZS , Lahm, E , Kulka, J . "Primary systemic therapy (PST) of locally advanced breast cancer using doxorubicin/docetaxel combination"
23, 2879-2880, 2003. Retrieved from:
13. Bonnefoi, H , Biganzoli, L , Mauriac, L . "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflimatory breast cancer"
Eur J Cancer 39, 1277-1283, 2003
14. Deo, SV , Purkayashta, J , Shukla, NK , Asthana, S . "Myocutaneous versus thoraco- abdominal flap cover for soft tissue defects following surgery for locally advanced and recurrent breast cancer"
J Surg Oncol
83, 31-35, 2003. Retrieved from:
15. Favret, AM , Carlson, RW , Goffinet, DR , Jeffrey, SS , Dirbas, FM , Stockdale, FE . "Locally advanced breast cancer: surgery necesary?"
7, 131-137, 2001. Retrieved from:
16. Griem, KL , Henderson, C , Gelman, R Ascoli D, Silver, B , Recht, A , et al., . "The 5 year results of a randomized trial of adjuvant radiation therapy after chemotherapy in the breast cancer patient treated with mastectomy"
J Clin Oncol
5, 1546-1555, 1978. Retrieved from:
17. Matsuda, MLDL , Laudico, AV , Cabaluna, ND , et al., . "Evidence based clinical practice guide lines on the diagnosis and management of breast cancer. Part II Locally advanced breast cancer, locally recurrent breast cancer and metastatic breast cancer"
Philip J Surg Spec 56, 135-1362, 2001
18. De la Pena, AS , Joson, RO , Cabaluna, ND , Dofitas, R , Lavalle, AM , Matsuda, MLDL . "A prospective randomized trial comparing three multimodality regimens for locally advanced breast cancer: an initial report of results treatment"
Philip J Surg Spec
52, 7-11, 1997. Retrieved from: